Replies to post #47237 on Biotech Values

[spartex]

Clark,

In some respects, many (even longs) have also written off DNDN after their approvable letter. The problem is that they became super bulls and went crazy buying shares in the $15+ price range which wasn't prudent. However, those who were deft could buy DNDN shares in the low $5's the morning after the FDA news. Price entry is one of the key decision points that an investor needs to make, not necessarily whether they will buy or not buy a particular company.

Regards,
Spartex

[DewDiligence]

FDA Approves Lyrica for Fibromyalgia

[Lyrica, the successor to PFE’s Neurontin, was already approved for neuropathic pain and epileptic seizure prevention.]

http://yahoo.reuters.com/news/articlehybrid.aspx?storyID=urn:newsml:reuters.com:20070621:MTFH00801_2...

>>
Thu Jun 21, 2007 4:53 PM ET

WASHINGTON, June 21 (Reuters) - Pfizer Inc. <PFE> won approval to promote the prescription drug Lyrica for treating fibromyalgia, U.S. health officials said on Thursday.

The medicine is the first approved drug treatment for the chronic disease which can cause debilitating pain and tenderness, sleep problems, stiffness and fatigue.

…The approval is an important advance for fibromyalgia "and provides a reason for optimism for the many patients who will receive pain relief with Lyrica," Dr. Steven Galson, director of FDA's Center for Drug Evaluation and Research, said in a statement.

"However, consumers should understand that some patients did not experience benefit in clinical trials. We still have more progress to make for treatment of this disorder," he added.
<<